Severe acute respiratory syndrome coronavirus

Roche receives CE mark for the use of saliva samples with cobas SARS-CoV-2 Qualitative test on cobas 6800/8800 Systems

Retrieved on: 
Friday, December 17, 2021
People, DJSI, Hoffmann-La Roche, Omicron, RNA, Genentech, Severe acute respiratory syndrome coronavirus 2, Death, Central nervous system, PCR, Essential medicines, COVID-19 testing, Veni, vidi, vici, Cough, European Centre for Disease Prevention and Control, Public health, Organic acid, World, COVID-19, Severe acute respiratory syndrome coronavirus, Family, Saliva, Risk, JAMA Network Open, Dow Jones, RO, Patient, System, Coinfection, Infection, Collection, Coronavirus, COV, Virus, Control, Genetically modified bacteria, Joint Medical Service (Germany), Ophthalmology, Severe acute respiratory syndrome, CHF, Human, ROG, Vaccine, Pharmaceutical industry, Medical device, Fine chemical, Chugai Pharmaceutical Co.

PLEASANTON, Calif., Dec. 17, 2021 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas® SARS-CoV-2 Qualitative test has received CE mark for the use of saliva samples in the detection of SARS-CoV-2 on the widely available, high-throughput cobas® 6800/8800 Systems. This non-invasive test is for any individual, including those suspected of COVID-19 and those without symptoms. Saliva sample collection represents a convenient testing approach for patients, who can easily self-collect their own samples.

Key Points: 
  • PLEASANTON, Calif., Dec. 17, 2021 /PRNewswire/ --Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas SARS-CoV-2 Qualitative test has received CE mark for the use of saliva samples in the detection of SARS-CoV-2 on the widely available, high-throughput cobas 6800/8800 Systems.
  • Saliva sample collection represents a convenient testing approach for patients, who can easily self-collect their own samples.
  • "Expanding sensitive testing to include a non-invasive, easy-to-collect sample type such as saliva helps to improve access to screening for more people.
  • The test also provides patients with the option to self-collect their saliva sample on site, following the instructions of a healthcare professional.

A New Class of Antiviral Therapy Could Treat COVID-19

Retrieved on: 
Thursday, December 9, 2021
Cell, University of California, San Diego, Research, National Institute on Drug Abuse, Technology, Disease, Pulmonary edema, SARS, National, Fred Hutchinson Cancer Research Center, Inflammation, Biochemistry, RNA transfection, Animal, News, Patient, Vaccine, University of California, San Francisco, Alpha, City, National Institute, HIV, Severe acute respiratory syndrome coronavirus, Virus, Government, Center, Biophysics, COVID-19, University, Viral load, Tips, San Francisco, Beta, MTEC, Gladstone Institutes, Doctor of Philosophy, Nose, Death, SAN, Immunity, TIP, Infection, United Kingdom, Severe acute respiratory syndrome coronavirus 2, UC, Beckman Research Institute, Pharmaceutical industry, Medical device

They showed, in animals, that TIPs dramatically reduced the amount of SARS-CoV-2 virus found in the lungs and protected the animals from disease.

Key Points: 
  • They showed, in animals, that TIPs dramatically reduced the amount of SARS-CoV-2 virus found in the lungs and protected the animals from disease.
  • "The design and use of TIPs has always held incredible promise of providing a simple-to-administer, highly effective antiviral strategy that can resist viral adaptation.
  • Weinberger's team has now developed a TIP for SARS-CoV-2the first antiviral with the capacity to track viral evolution.
  • The idea for TIPs was conceived to address problems in HIV treatment with an approach that could overcome antiviral drug resistance and act as a single-administration therapy.

Abpro Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron Variant

Retrieved on: 
Thursday, December 9, 2021
Antibody, Risk, Company, Eye, Delta, GLOBE, Severe acute respiratory syndrome coronavirus, EUA, Infection, Omicron, Immune system, Safety, Vaccine, Patient, COVID, Cancer, Lance, Autoimmunity, Time, COVID-19, 310, ABP, Severe acute respiratory syndrome coronavirus 2

ABP 310 was studied against all currently prevalent and emerging SARS-CoV-2 variants of concern, including Omicron and Delta, and SARS-CoV, in a completed preclinical study.

Key Points: 
  • ABP 310 was studied against all currently prevalent and emerging SARS-CoV-2 variants of concern, including Omicron and Delta, and SARS-CoV, in a completed preclinical study.
  • Based on evidence currently available from the study, the mutations in the Omicron variant do not escape binding and neutralization by ABP 310.
  • Based on preclinical pseudovirus data and structural modeling showing that ABP 310 retains activity and potency against Omicron variant mutations, Abpro plans to continue advancing ABP 310 on the path towards EUA approval as early as 2022.
  • This is a great initial validation of how our neutralizing antibody therapy can withstand the test of time and diverse geographical origins.

Biotech Sector's Response to Omicron Panic Should be Swift and Effective

Retrieved on: 
Tuesday, December 7, 2021
NYSE, Reuters, PFE, S, Research, Delta, COVID-19, CSE, Technology, JPMorgan Chase, Severe acute respiratory syndrome coronavirus, Pfizer–BioNTech COVID-19 vaccine, Panic, Coronaviridae, NVAX, Wuxi, Safety, Coronavirus, BBC, COVID, RNA transfection, Novavax, Method, Ohio State University, Bloomberg Television, BioNTech, Pandemic, Government, Protein, DTH, FDA, OSU, SE, NASDAQ, MRNA, BNTX, News, Interview, SARS2, Severe acute respiratory syndrome coronavirus 2, Vaccine, Pharmaceutical industry, Animal

"Research suggests that a pan-sarbecovirus vaccine could potentially prevent additional emergent variants and help end the Covid-19 pandemic."

Key Points: 
  • "Research suggests that a pan-sarbecovirus vaccine could potentially prevent additional emergent variants and help end the Covid-19 pandemic."
  • Sarbecoviruses are a subset of the Coronaviridae family, which includes the emerging SARS2 variants Delta and Omicron.
  • BioVaxys recently filed apatent application for its haptenized viral antigen vaccine platform to elicit a broad cross-reactive immune response against most or all sarbecoviruses.
  • According to Burton, Modernashould know whether their current COVID-19 vaccine can provide protection against Omicron in the "next couple weeks."

Biotech Sector's Response to Omicron Panic Should be Swift and Effective

Retrieved on: 
Tuesday, December 7, 2021
NYSE, Reuters, PFE, S, Research, Delta, COVID-19, CSE, Technology, JPMorgan Chase, Severe acute respiratory syndrome coronavirus, Pfizer–BioNTech COVID-19 vaccine, Panic, Coronaviridae, NVAX, Wuxi, Safety, Coronavirus, BBC, COVID, RNA transfection, Novavax, Method, Ohio State University, Bloomberg Television, BioNTech, Pandemic, Government, Protein, DTH, FDA, OSU, SE, NASDAQ, MRNA, BNTX, News, Interview, SARS2, Severe acute respiratory syndrome coronavirus 2, Vaccine, Pharmaceutical industry, Animal

VANCOUVER, BC, Dec. 7, 2021 /PRNewswire/ -- USA News Group - Despite a level of panic that JP Morgan has already downplayed in its 2022 forecasts, the market's reaction to the latest COVID-19 variant scare (omicron) has been swift. A multitude of reactionary strategies have begun to swirl, including injecting more boosters from the original vaccine, or fast-tracking newly revamped vaccines. As COVID researchers rush to learn about the new variant, the biotech sector is responding in kind, with new developments already underway from companies such as BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), Moderna, Inc. (NASDAQ: MRNA), BioNTech SE (NASDAQ: BNTX), and Pfizer, Inc. (NYSE: PFE), as well as Novavax, Inc. (NASDAQ: NVAX).

Key Points: 
  • "Research suggests that a pan-sarbecovirus vaccine could potentially prevent additional emergent variants and help end the Covid-19 pandemic."
  • Sarbecoviruses are a subset of the Coronaviridae family, which includes the emerging SARS2 variants Delta and Omicron.
  • BioVaxys recently filed apatent application for its haptenized viral antigen vaccine platform to elicit a broad cross-reactive immune response against most or all sarbecoviruses.
  • According to Burton, Modernashould know whether their current COVID-19 vaccine can provide protection against Omicron in the "next couple weeks."

Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection

Retrieved on: 
Monday, September 27, 2021
Center for Biologics Evaluation and Research, Infection, UCSF, Biotechnology, Food, Nature, HEP, Hepatitis B, Liver disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Annual report, Influenza, NASDAQ, Severe acute respiratory syndrome coronavirus, FDA, Cancer, Chronic liver disease, Drug discovery, CEO, Death, Hijack, Center, HIV/AIDS, COVID-19, IND, Drug development, Gilead Sciences, Clinical research, List, HIV, HBV, SEC, GLOBE, Pharmaceutical industry, Vaccine

Promising results from animal studies have been presented at scientific meetings ( Hep Dart 2019 Presentation and ASGCT 2020 Presentation ) by Enochian BioSciences Inventor and Co-Founder, Dr. Serhat Gumruku.

Key Points: 
  • Promising results from animal studies have been presented at scientific meetings ( Hep Dart 2019 Presentation and ASGCT 2020 Presentation ) by Enochian BioSciences Inventor and Co-Founder, Dr. Serhat Gumruku.
  • The information provided in the FDAs written comments also help us to accelerate the development of those potential products.
  • Enochian BioSciences, Inc. is a biopharmaceutical company focused on developing innovative platforms for gene-modified cellular and immune therapies to potentially cure and treat deadly diseases.
  • Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Agilex Biolabs Announced as Citeline Award Finalist for COVID-19 Vaccine Toxicology Preclinical Research

Retrieved on: 
Friday, September 24, 2021
MSD, RATS, Safety, Clinical trial, Vaccine, PK, Accreditation, GLP, BD, LC-MS/MS, Biomarker, Cell biology, Prix Iris for Most Successful Film Outside Quebec, Toxicology, Flow cytometry, Industry, Dog, Program, Severe acute respiratory syndrome coronavirus, Immunology, Trial of the century, COVID-19, PD, Severe acute respiratory syndrome coronavirus 2, Research, Tran, NATA, A3, Laboratory, Mesoscale, OECD, Chappell, Tapley, Fine chemical, Pharmaceutical industry, Television

Agilex Biolabs offers advanced bioanalytical services for biotech companies and delivers toxicology services to support pre-clinical and early phase research within their TetraQ, division.

Key Points: 
  • Agilex Biolabs offers advanced bioanalytical services for biotech companies and delivers toxicology services to support pre-clinical and early phase research within their TetraQ, division.
  • Dr. Peter Tapley, Director Toxicology at TetraQ, said the research submitted for the Citeline Award focussed on preclinical assessment of the safety and tolerability of a SARS-CoV-2 Sclamp protein subunit COVID-19 vaccine in rats.
  • "This research highlights the pathways that biotech companies can take for rapid vaccine development, and how the Australian research, regulatory and clinical infrastructure provides a supportive environment."
  • Agilex Biolabs also offers toxicology services through TetraQ an Agilex Biolabs company, an established GLP toxicology facility in Australia.

Failure of National Pandemic Plan Examined in the Journal of American Physicians and Surgeons

Retrieved on: 
Tuesday, September 21, 2021
COVID-19, Chloroquine, Trump administration political interference with science agencies, Severe acute respiratory syndrome coronavirus, AAPS, Patient, Association, Physician, Hydroxychloroquine, Association of American Physicians and Surgeons, Government, Coronavirus, EUA, Disease, Journal, Human, HCQ, Task force, SARS, IND, Presidency of Donald Trump, Emergency Use Authorization, GLOBE, Pharmaceutical industry

Americans lives have been tragically disrupted and permanently altered by the COVID-19 pandemic.

Key Points: 
  • Americans lives have been tragically disrupted and permanently altered by the COVID-19 pandemic.
  • The U.S. has had a validated National Pandemic Response Plan since 2000, and it was updated in 2017.
  • This virus, SHCO14-CoV, was analogous to the 2003 SARS virus, and was capable of jumping directly from bats to humans.
  • The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS) , a national organization representing physicians in all specialties since 1943.

AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD)

Retrieved on: 
Wednesday, August 25, 2021
Cancer, Company, Lists of diseases, Population, Delta, Private Securities Litigation Reform Act, Human, Therapy, Special access program, Severe acute respiratory syndrome coronavirus 2, Degenerative disease, Viral load, The Wall Street Journal, GLOBE, Method, Survival, Amnesia, Leadership, The Institute, Research, Erasmus MC, Disease, Utah, Doctor of Philosophy, PSLRA, Influenza, Severe acute respiratory syndrome coronavirus, NYSE, Clinical trial, AIM, Mortality, Safety, EAP, Patient, Immunity, Utah State University, Vaccine, Infection, Antiviral drug, COVID-19, MD, Pharmaceutical industry

Developing an effective therapy is critical for relieving the socioeconomical impact of PCCD and its medical burden on the population.

Key Points: 
  • Developing an effective therapy is critical for relieving the socioeconomical impact of PCCD and its medical burden on the population.
  • The results of some individual symptoms are very dramatic, said Lapp, the EAPs lead investigator.
  • The results clearly show a significant reduction of one or more symptoms of PCCD in patients after the administration of Ampligen.
  • The study is part of AIMs work to develop Ampligen as a potential therapy against SARS-CoV-2 and other respiratory viruses.

Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates

Retrieved on: 
Monday, August 16, 2021
Clinical trial, World Health Organization, Research, Week, G&A, Nobel Prize, Vaccine, Cirrhosis, Disease, Hepatocellular carcinoma, Cocrystal, Severe acute respiratory syndrome coronavirus, Company, Private Securities Litigation Reform Act, Degenerative disease, SEC, FDA, Annual report, World, Mouse, Enzyme, Gastroenteritis, HCV, Liver, Infection, CEO, Government, Injection, COVID-19, COCP, Coronavirus Scientific Advisory Board (Turkey), Virus, Board, WHO, Death, Risk, Merck, Plasma protein binding, CFO, Influenza A virus, Trial of the century, CMOS, Cros, Russell, GLOBE, Software, Severe acute respiratory syndrome coronavirus 2, Nasdaq, R, Pharmaceutical industry

BOTHELL, Wash., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (Cocrystal or the Company), a clinical-stage biotechnology company, reports financial results for the three and six months ended June 30, 2021, and provides updates on its antiviral pipeline, milestones and business activities.

Key Points: 
  • BOTHELL, Wash., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (Cocrystal or the Company), a clinical-stage biotechnology company, reports financial results for the three and six months ended June 30, 2021, and provides updates on its antiviral pipeline, milestones and business activities.
  • We believe our capital is sufficient to fund planned operations beyond 2024, including clinical trials, as we advance toward commercialization.
  • As anticipated, Cocrystal reported no revenues for the second quarter of 2021 compared with $554,000 in revenues for the second quarter of 2020.
  • In January 2021, the influenza A/B program was advanced for continued development of the antiviral agents at Merck.